The Hygeia Group of Hospitals Expands Clinerion’s Global Network of Hospitals into Greece
The Hygeia Group, comprising three hospitals in Athens, Greece, joins Clinerion’s hospital network, and expands Clinerion’s Patient Network Explorer footprint in Europe. The Hygeia Group comprises three hospitals:
- the Hygeia hospital, a diagnostic and therapeutic center and general hospital in Athens, Greece with 315 beds;
- the Mitera Hospital, a general hospital specializing in maternity, gynecology and children’s health in Athens, Greece with 459 beds;
- the Leto Hospital, a maternity and gynecology hospital, and surgical center in Athens, Greece with 100 beds.
The Hygeia Hospital is the only hospital in Greece with a Joint Commission International (JCI) Gold Seal accreditation for quality and safety in healthcare. The group currently conducts above 80 clinical trials per year. Joining Clinerion’s Patient Network Explorer platform will bring more innovative treatments to the patients of the Hygeia Group’s hospitals and clinics, and give their physicians more options in treating their patients. The group will also gain more exposure to global clinical trials run by international pharmaceutical companies and contract research organizations. Drug developers working on innovative treatments will now benefit from access to these new geographies and clinics with strong therapeutic focus. “The strong oncology orientation of our hospitals along with the high-quality oncology staff provide a great opportunity to all stakeholders to enhance clinical trials with novel agents and combinations for our patients’ benefit,” says Mr. Andreas Kartapanis, CEO of the Hygeia Group. “The Hygeia Group has state-of-the-art infrastructure and equipment, and a roster of expert clinicians,” says Ian Rentsch, CEO of Clinerion. “This will be a great benefit to pharma companies and CROs looking to accelerate their drug trials in Greece.”
About Clinerion
Clinerion enables early patient access to innovative treatments through real-patient data solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's Patient Network Explorer accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-driven protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion's solutions comply with international patient privacy and data security regulations. Clinerion website:
www.clinerion.com
Clinerion’s Patient Network Explorer:
www.clinerion.com/index/OverviewOurSolutions/Clineriontechnologysolution
For more information, please contact: Le Vin Chin Head of Marketing and Communications Clinerion Ltd Margarethenstrasse 47, CH-4053 Basel, Switzerland Tel.: +41 61 865 60 54 media@clinerion.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
